Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 3/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879013 | 1.00 | NPY5R (0.37) | NPY5RBTKKMT2ASGK1CSNK1A1 | |
| SCHEMBL2879012 | 1.00 | NPY5R (0.37) | NPY5RBTKKMT2ASGK1CSNK1A1 | |
| SCHEMBL2879071 | 0.90 | HTR2B (0.39) | NPY5RBRD4 | |
| SCHEMBL2884478 | 0.90 | HTR2B (0.39) | NPY5RBRD4 | |
| SCHEMBL2879075 | 0.90 | HTR2B (0.39) | NPY5RBRD4 | |
| SCHEMBL2879010 | 0.85 | NPY5R (0.37) | NPY5RBTKKMT2ASGK1CSNK1A1 | |
| SCHEMBL2879515 | 0.85 | NPY5R (0.37) | NPY5RBTKKMT2ASGK1CSNK1A1 | |
| SCHEMBL2881783 | 0.85 | NPY5R (0.36) | NPY5RBTKSGK1 | |
| SCHEMBL2879017 | 0.85 | NPY5R (0.36) | NPY5RBTKSGK1 | |
| SCHEMBL2879019 | 0.85 | NPY5R (0.36) | NPY5RBTKSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| CN-100567270-C | Sulfone amide derivative | BANYU PHARMA CO LTD (JP) | 2009-12-09 | — | — | CN | claimed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | claimed |
| CN-1922155-A | Novel Sulfonamide Derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | claimed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | claimed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| CN-100567270-C | Sulfone amide derivative | BANYU PHARMA CO LTD (JP) | 2009-12-09 | — | — | CN | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| CN-1922155-A | Novel Sulfonamide Derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | NPY5R 3/4885BTK 1120/4885KMT2A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.